Vericel (VCEL) Amortization of Deferred Charges (2021 - 2026)
Vericel (VCEL) reported Amortization of Deferred Charges of $1.4 million for Q1 2026, up 2427.78% on a YoY basis from $54000.0 in Q1 2025, and up 2427.78% sequentially from $54000.0 in Q4 2025.
Vericel (VCEL) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Vericel (VCEL) has 6 years of Amortization of Deferred Charges data on file, last reported at $1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 2427.78% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (down 77.06% YoY), and the FY2025 full-year result was $215000.0, down 96.77% from the prior year.
- Amortization of Deferred Charges advanced to $1.4 million in Q1 2026, from $54000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $5.9 million in Q4 2023 to a low of -$2.5 million in Q3 2025.
- A 5-year average of $1.1 million and a median of $1.1 million in 2022 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges soared 3030.19% in 2024 and slumped 253.16% in 2025, its largest moves.
- Tracing VCEL's Amortization of Deferred Charges over 5 years: stood at $1.1 million in 2022, then soared by 436.21% to $5.9 million in 2023, then sank by 74.41% to $1.5 million in 2024, then tumbled by 96.43% to $54000.0 in 2025, then jumped by 2427.78% to $1.4 million in 2026.
- Business Quant data shows VCEL's Amortization of Deferred Charges at $1.4 million in Q1 2026, $54000.0 in Q4 2025, and -$2.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 54,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Sep 30, 2025 | -2.54 Mn |
| Sep 30, 2025 | -2.54 Mn |
| Jun 30, 2025 | 2.65 Mn |
| Jun 30, 2025 | 2.65 Mn |
| Mar 31, 2025 | 54,000.00 |
| Mar 31, 2025 | 54,000.00 |
| Dec 31, 2024 | 1.51 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Mar 31, 2024 | 54,000.00 |
| Mar 31, 2024 | 54,000.00 |
| Dec 31, 2023 | 5.91 Mn |
| Dec 31, 2023 | 5.91 Mn |